In MC-38 syngeneic tumor model, (1S, 3R)‐RSL3 (RSL), a glutathione peroxidase 4 inhibitor, effectively promoted the antitumor effect of anti-PD-1 treatment in vivo. Here, PDCD1 is linked to neoplasm.